Hikma Pharmaceuticals is a multinational pharmaceutical company that specializes in the development, manufacturing, and marketing of branded and non-branded generic and in-licensed pharmaceutical products. Founded in 1978 in Amman, Jordan, Hikma has grown into a significant player in the global pharmaceutical industry with operations in over 50 countries.

Hikma was founded over 45 years ago with the mission to make high-quality medicines accessible to those who need them. This has been our focus every day since, and now, with new leadership and a refreshed, ambitious strategic focus, we are well placed for our next chapter of growth.

Key Areas of Focus:

1. Generics: Hikma is well-known for its extensive range of generic medications, which are equivalent to brand-name drugs in terms of dosage, strength, route of administration, quality, performance, and intended use.
2. Injectables: The company has a strong presence in the injectable drugs market, providing critical medications for hospitals and healthcare facilities. This includes antibiotics, anesthesia, pain management, and anti-infectives.
3. Branded: Hikma markets branded generics mainly in the Middle East and North Africa (MENA) region, where it enjoys a robust market presence and brand recognition.

Financial Performance:

Hikma Pharmaceuticals is publicly traded on the London Stock Exchange under the ticker symbol HIK. The company has demonstrated steady financial growth through a combination of organic growth, strategic acquisitions, and expansion into new markets. Their revenue streams are diversified across the US, MENA, and Europe.

Strategic Acquisitions and Partnerships:

Over the years, Hikma has expanded its portfolio and market reach through various acquisitions and partnerships. Notable acquisitions include the purchase of Boehringer Ingelheim’s Roxane Laboratories in the US, which significantly enhanced Hikma’s capabilities in the generics sector, particularly in injectables and oral solids.

Research and Development:

Hikma invests heavily in R&D to support its growth and maintain a competitive edge in the pharmaceutical industry. The company focuses on developing complex generics and specialty products, leveraging its manufacturing and scientific expertise to meet regulatory standards across different regions.

Corporate Responsibility:

Hikma is committed to corporate social responsibility (CSR) and sustainability. The company focuses on improving healthcare access, supporting community health initiatives, and ensuring environmental sustainability in its operations. They also adhere to high ethical standards in their business practices.

Global Reach and Manufacturing:

Hikma operates manufacturing facilities in the US, Europe, and MENA, ensuring a reliable supply chain and the ability to meet diverse market needs. Their global footprint allows them to serve a broad customer base, including hospitals, pharmacies, and other healthcare providers.

In summary, Hikma Pharmaceuticals is a dynamic and growing global pharmaceutical company with a strong emphasis on generic and injectable medicines. Its strategic acquisitions, extensive R&D investments, and commitment to corporate responsibility position it as a key player in the global pharmaceutical landscape.

Hikma Pharmaceuticals USA Inc.
200 Connell Drive, 4th Floor
Berkeley Heights, NJ 07922
Phone: (908) 673-1030

Website: https://www.hikma.com

Careers: www.hikma.com/careers

Hikma Pharmaceuticals USA Inc.  – NDC products

Hikma Pharmaceuticals USA Inc. manufactures, markets and/or distributes more than 185 drugs in the United States. Medications listed here may also be marketed under different names in different countries.

NDC labeler, manufacturer of drugs and pharmaceuticals

Products with assigned NDCs are displayed.  Select the NDC to see product information.